The Menarini Group, an Italy-based pharmaceutical and diagnostics company, announced on Thursday that it has received marketing authorisation from the European Commission for ELZONRIS (tagraxofusp) as monotherapy intended for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
This approval follows the positive opinion received from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is based on the outcome of the clinical trial conducted in patients with treatment-naïve or previously-treated BPDCN.
The product has received orphan designation in Europe, and is now the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy in Europe to address this high unmet medical need.
Iterion Therapeutics reports first patient dosed in clinical study of tegavivint
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288
FDA issues EUA for Boehringer Ingelheim's IVOMEC (ivermectin) 1% Injection
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Hologic receives FDA approval for Aptima HPV assay as primary screening option
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer